Sanofi Q3 Sales €12.43B on Record Dupixent

Sanofi beat third-quarter expectations with adjusted earnings of about €2.91 per share and net sales of €12.43 billion, driven largely by record Dupixent performance. Dupixent crossed the €4 billion mark for the first time—reported at roughly €4.16–€4.2 billion—up about 26% year‑on‑year and projected to exceed €21 billion at peak. Strong Dupixent growth and new pharma launches including Altuviiio and Ayvakit offset a notable decline in vaccine sales, especially seasonal influenza, while foreign‑exchange headwinds weighed on results. Sanofi reiterated full‑year guidance for high single‑digit sales growth and low‑double‑digit business EPS growth and is continuing a €5 billion share buyback program. Management said it is in ongoing talks with the U.S. administration on drug‑pricing, is increasing U.S. investments and dealmaking to bolster the pipeline ahead of Dupixent’s expected 2031 patent expiry, and is advancing more than a dozen late‑stage candidates.